# US 9,750,853 B2 · Stent with preferential coating > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,853 B2 - Document ID: US9750853B2 - Status: Granted - Kind: B2 - Application number: 15/184,714 - Filed: 2016-06-16 - Published: 2016-10-06 - Granted: 2017-09-05 - Earliest claimed: 2007-09-28 - Assignees: Abbott Cardiovascular Systems Inc. - Applicants: Abbott Cardiovascular Systems Inc. - Inventors: Bin Huang; David C. Gale; Daniel A. Castro; Vincent J. Gueriguian - Web page: https://patentgrep.com/patent/US9750853B2 ## CPC - A61L 31/10: Macromolecular materials - A61F 2/86: Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure - A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin - A61L 31/022: {Metals or alloys} - A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)} - A61L 31/08: Materials for coatings - A61L 31/148: {Materials at least partially resorbable by the body} - A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} - B05D 1/02: performed by spraying - B05D 1/18: performed by dipping - B05D 1/32: using means for protecting parts of a surface not to be coated, e.g. using stencils, resists - A61F 2240/001: Designing or manufacturing processes - A61F 2250/0051: differing in tissue ingrowth capacity, e.g. made from both ingrowth-promoting and ingrowth-preventing parts - A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body - A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus - A61L 2420/02: Methods for coating medical devices - A61L 2420/08: Coatings comprising two or more layers - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - B05D: PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL (conveying articles or workpieces through baths of liquid B65G, e.g. B65G49/02) ## Abstract This invention relates to stents, a type of implantable medical device, with an antiproliferative coating and a prohealing luminal coating and methods of fabricating stents with an antiproliferative coating and a prohealing luminal coating. ## Claims ### Claim 1 A method for coating a stent body, the method comprising: crimping a stent body; forming a prohealing coating above a luminal surface of the crimped stent body by applying a coating material comprising a prohealing agent that promotes cell growth on the luminal surface of the crimped stent body; and forming an antiproliferative coating above an abluminal surface of the crimped stent body by applying a coating material comprising an antiproliferative active agent on the abluminal surface of the crimped stent body, wherein the antiproliferative coating is formed at the same time as the prohealing coating. ### Claim 2 (depends on 1) The method of claim 1, wherein the crimping allows selective application of the coating material to the luminal surface and the abluminal surface. ### Claim 3 (depends on 1) The method of claim 1, wherein the coating material comprising the prohealing agent is applied by inserting a sprayer nozzle inside of a lumen of the crimped stent body and spraying the coating material comprising the prohealing agent over the luminal surface. ### Claim 4 (depends on 1) The method of claim 1, wherein struts of the crimped stent body are close together which at least partially shields sidewalls and the abluminal surface from the coating material comprising the prohealing agent applied to the luminal surface. ### Claim 5 (depends on 1) The method of claim 1, wherein the coating material comprising the antiproliferative agent is applied by spraying the abluminal surface of the crimped stent body with the coating material comprising the antiproliferative agent from a sprayer nozzle. ### Claim 6 (depends on 1) The method of claim 1, wherein struts of the crimped stent body are close together which reduces or prevents exposure of the luminal surface and sidewalls of the struts to the coating material comprising the antiproliferative agent applied to the abluminal surface. ### Claim 7 (depends on 1) The method of claim 1, wherein the stent body is made of a metal. ### Claim 8 (depends on 1) The method of claim 1, wherein the stent body is made of a bioabsorbable polymer. ### Claim 9 (depends on 1) The method of claim 1, wherein the prohealing agent comprises a protein, peptide, or antibody that attracts and binds endothelial cells, or a substance that attracts and binds endothelial progenitor cells, or the antibody CD-34, or the antibody CD-133, or the antibody vegf type 2 receptor, or any combinations thereof. ### Claim 10 (depends on 1) The method of claim 1, wherein the antiproliferative coating comprises everolimus and wherein the stent body comprises poly(L-lactide).